A5032795508- Cervical Cancer and HPV Research
- Genital Health and Disease
- Hepatitis B Virus Studies
- Global Cancer Incidence and Screening
- Reproductive tract infections research
- Endometrial and Cervical Cancer Treatments
- Vaccine Coverage and Hesitancy
- Head and Neck Cancer Studies
- Esophageal Cancer Research and Treatment
- Molecular Biology Techniques and Applications
- Colorectal and Anal Carcinomas
- Microbial infections and disease research
- Cardiac Valve Diseases and Treatments
- Cultural Competency in Health Care
- Animal Virus Infections Studies
- Cancer Risks and Factors
- Hepatitis Viruses Studies and Epidemiology
- Cardiac, Anesthesia and Surgical Outcomes
- Liver Disease Diagnosis and Treatment
- Insect-Plant Interactions and Control
- vaccines and immunoinformatics approaches
- Vascular anomalies and interventions
- COVID-19 and healthcare impacts
- Women's cancer prevention and management
- Interpreting and Communication in Healthcare
Institut Català d'Oncologia
2015-2024
Institut d'Investigació Biomédica de Bellvitge
2015-2024
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
2009-2024
Institut Català d'Ornitologia
2012-2024
Instituto de Salud Carlos III
2023-2024
Centre for Biomedical Network Research on Rare Diseases
2024
Duran i Reynals Hospital
2023
Centro de Investigación Biomédica en Red de Cáncer
2017-2020
Training Programs in Epidemiology and Public Health Interventions Network
2020
Bellvitge University Hospital
2020
The knowledge that persistent human papillomavirus (HPV) infection is the main cause of cervical cancer has resulted in development prophylactic vaccines to prevent HPV and assays detect nucleic acids virus. WHO launched a Global Initiative scale up preventive, screening, treatment interventions eliminate as public health problem during 21st century. Therefore, our study aimed assess existing burden baseline from which effect this initiative.
Since 2006, many countries have implemented publicly funded human papillomavirus (HPV) immunisation programmes. However, global estimates of the extent and impact vaccine coverage are still unavailable. We aimed to quantify worldwide cumulative HPV programmes up 2014, potential on future cervical cancer cases deaths.
WHO/UNICEF estimates for HPV vaccination coverage from 2010 to 2019 are analyzed against the backdrop of 90% target by 2030 set in recently approved global strategy cervical cancer elimination as a public health problem. As June 2020, 107 (55%) 194 WHO Member States have introduced vaccination. The Americas and Europe far regions with most introductions, 85% 77% their countries having already respectively. A record number introductions was observed 2019, which low- middle- income (LMIC)...
Information on human papillomavirus (HPV) type distribution is necessary to evaluate the potential impact of current and future HPV vaccines. We estimated relative contribution (RC) invasive cervical cancer (ICC) precancerous lesions nine types (HPV 6/11/16/18/31/33/45/52/58) included in an vaccine currently under development.Estimations ICC were based international study 8,977 positive cases estimations extracted from a published meta-analysis including 115,789 women. Globocan 2008 2010...
Abstract The age‐standardised incidence of cervical cancer in Europe varies widely by country (between 3 and 25/100000 women‐years) 2018. Human papillomavirus (HPV) vaccine coverage is low countries with the highest screening performance heterogeneous among European countries. A broad group delegates scientific professional societies organisations endorse principles WHO call to eliminate as a public health problem, also Europe. All nations should, 2030, reach at least 90% HPV girls age 15...
Abstract At the 2023 EUROGIN workshop scientific basis for strategies to accelerate elimination of cervical cancer and its causative agent, human papillomavirus (HPV) were reviewed. Although some countries have reached key performance indicators toward (>90% girls HPV vaccinated >70% women screened), most are yet reach these targets, implying a need improved strategies. Gender‐neutral vaccination, even with moderate vaccination coverage was highlighted as strategy achieve more rapidly....
The Americas region has the lowest (North America) and second highest (Latin America Caribbean) cervical cancer (CC) mortality worldwide. lack of reliable data on screening coverage in hinders proper monitoring World Health Organization (WHO) CC elimination initiative. For this synthetic analysis, we searched from official sources national health surveys, supplemented with a formal WHO country consultation. Context were obtained (income, expenditure, inequality-adjusted human development...